OncoMatch/Leukemia — Acute Lymphoblastic (ALL)/BCR::ABL1 (Ph+)
Leukemia — Acute Lymphoblastic (ALL)BCR::ABL1 (Ph+) Clinical Trials
BCR::ABL1 fusion — the Philadelphia chromosome — occurs in approximately 25% of adult ALL and 3–5% of pediatric ALL and historically defined a poor-prognosis subtype now transformed by TKI addition to chemotherapy. Ponatinib plus blinatumomab achieves high MRD-negative CR rates in newly diagnosed Ph+ ALL without intensive chemotherapy. Trials investigate chemotherapy-free TKI/immunotherapy combinations, asciminib in Ph+ ALL, and sequential or maintenance TKI strategies guided by MRD.
Top recruiting BCR::ABL1 (Ph+) Leukemia — Acute Lymphoblastic (ALL) trials
Ranked by phase and US site count.
See all trials matched to your profile →Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Nanfang Hospital, Southern Medical University
More BCR::ABL1 (Ph+) Leukemia — Acute Lymphoblastic (ALL) trials
11 international trials (no US sites)
Browse other molecular targets with active Leukemia — Acute Lymphoblastic (ALL) trials.